-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STAR-0602 in Vaginal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Vaginal Cancer Drug Details: STAR-0602 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-038 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLX-038 in Ovarian Cancer Drug Details: PLX-038 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Repotrectinib in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Repotrectinib in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Repotrectinib in Melanoma Drug Details: Repotrectinib (Augtyro) acts as an anti-neoplastic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Equecabtagene Autoleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Equecabtagene Autoleucel in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Equecabtagene Autoleucel in Relapsed Multiple Myeloma Drug Details: Equecabtagene autoleucel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glofitamab in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glofitamab in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glofitamab in Non-Hodgkin Lymphoma Drug Details: Glofitamab (Columvi) is a bispecific monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-011 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Systemic Sclerosis (Scleroderma) Drug Details: FT-011 (SHP-627) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-576 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-576 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FT-576 in Relapsed Multiple MyelomaDrug Details:FT-576 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-576 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-576 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FT-576 in Refractory Multiple MyelomaDrug Details:FT-576 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-001 in Leber Congenital Amaurosis (LCA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-001 in Leber Congenital Amaurosis (LCA) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...